The pharmacy field, often viewed as a stable and essential component of healthcare, has numerous hidden struggles that affect both the employees and the safety of patients. The experiences of pharmacy professionals, particularly during the intense summer of 2016, highlight the urgent need for reforms in the workplace. Long hours, lack of breaks, and overwhelming
Health
Recent findings from a comprehensive study presented at the ECTRIMS annual meeting highlight a troubling trend in the treatment of relapsing multiple sclerosis (MS). An analysis of French registry data indicates that women are significantly less likely than men to receive essential disease-modifying treatments (DMTs) for their condition. This disparity raises critical questions about factors
The federal government has taken a significant step in addressing the escalating costs of insulin by filing a lawsuit against three major pharmacy benefit managers (PBMs) — Caremark, Express Scripts, and OptumRx. These entities dominate the prescription drug market, handling approximately 80% of all U.S. prescriptions. The Federal Trade Commission (FTC) claims that their practices
The realm of public health is in a precarious position as the intersection of politics and science becomes increasingly pronounced. The prospect of Robert F. Kennedy Jr. influencing public health policy under a potential Trump administration raises questions about the implications for organizations like the Centers for Disease Control and Prevention (CDC) and the Food
The intersection of health, policy, and emerging research findings provides a rich terrain for inquiry, particularly in the contemporary landscape marked by rapid change and complexity. A plethora of recent studies and events reflects crucial health trends, ranging from dietary impacts on metabolic health to changes in healthcare policy and drug safety. This article endeavors
The recent approval by the U.S. Food and Drug Administration (FDA) of ribociclib, known commercially as Kisqali, represents a significant leap forward in the treatment landscape for early-stage high-risk breast cancer. Previously available only for patients experiencing metastatic disease, ribociclib has now earned a place in the adjuvant therapy toolbox for individuals diagnosed with hormone
Bladder cancer, particularly muscle-invasive bladder cancer (MIBC), has long posed significant challenges in clinical management. Traditional treatment strategies have incorporated neoadjuvant chemotherapy followed by radical cystectomy, yet many patients continue to experience relapse and eventual mortality. The emerging findings from the NIAGARA trial present a potentially transformative approach by integrating durvalumab (Imfinzi), an immune checkpoint
The landscape of cancer treatment is continually evolving with innovative therapies that promise improved outcomes for patients. Recently, significant advancements have emerged in the treatment of locally advanced or metastatic squamous cell carcinoma of the anal canal (SCAC) through immunotherapy. A pivotal Phase III clinical trial has shed light on the effectiveness of retifanlimab (brand
Menopause marks a significant transition in a woman’s life, often accompanied by a plethora of physical and hormonal changes. One of the less-discussed yet vital issues that arise during menopause is the increased risk of insulin resistance, a condition where the body’s cells become less responsive to insulin. This hormone is pivotal in regulating blood
In the ever-evolving landscape of health policies and societal challenges, recent events shed light on critical issues affecting public health, political discourse, and social behaviors across various demographics. This article aims to explore these developments while offering a fresh analysis of their broader implications. Former President Donald Trump’s proposal for providing free in vitro fertilization